M42 Strengthens Position as Middle East’s Largest Healthcare Firm with New Restructure and Expansion Plans

You are currently viewing M42 Strengthens Position as Middle East’s Largest Healthcare Firm with New Restructure and Expansion Plans
Credit : https://www.g42.ai/application/

Prime Highlights:

M42, the Middle East’s largest healthcare company, introduces a new operational structure to enhance its global presence, with 480 clinics across 26 countries.

The company now operates through four divisions—Global Patient Care, Integrated Health Solutions, Digital Health Solutions, and AI Life Sciences—each aimed at advancing healthcare services and innovation.

M42 is actively exploring mergers, acquisitions, and global partnerships to strengthen its capabilities, particularly in AI, healthcare precision, and predictive healthcare.

Key Background:

Abu Dhabi-based M42, the largest healthcare holding company in the Middle East, has unveiled a new operational structure aimed at enhancing its regional and global presence. Formed in 2022 through the merger of Mubadala’s healthcare assets and G42, M42 now operates 480 clinics across 26 countries, employing over 20,000 people. The restructuring is designed to increase the company’s agility and expand its healthcare services globally, building on its strong foundation in the UAE.

The newly formed structure includes four key verticals: Global Patient Care, Integrated Health Solutions, Digital Health Solutions, and AI Life Sciences. The Global Patient Care division integrates M42’s UAE-based and international healthcare assets, providing services to 15 million patients annually. Dimitris Moulavasilis will lead this division. The Integrated Health Solutions vertical will focus on national healthcare programs, including genomics, data services, and clinical research, under the leadership of Dr. Fahed Al Marzooqi.

Digital Health Solutions will prioritize the scaling of AI-based solutions to improve patient outcomes and healthcare access both locally and internationally, with Kareem Shahin serving as CEO. Meanwhile, the AI Life Sciences division will target advancements in drug discovery and development, using artificial intelligence to enhance capabilities in the life sciences field. Dr. Fahed will serve as the acting CEO of this division until a permanent appointment is made.

M42 is also pursuing strategic mergers and acquisitions to expand its portfolio. Managing Director and Group CEO Hasan Jasem Al Nowais emphasized the company’s openness to global opportunities and partnerships, particularly in the fields of healthcare precision, prevention, and prediction. Recently, M42 expanded its Gulf footprint, entering Bahrain in collaboration with Mumtalakat, Bahrain’s sovereign wealth fund, and forming a strategic partnership with the UAE Ministry of Defence in the northern emirates. In 2023, M42 further bolstered its capabilities by acquiring Diaverum, a leading provider of renal care services with operations in 24 countries and over 450 clinics.